|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SH2D5 |
Gene summary for SH2D5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SH2D5 | Gene ID | 400745 |
| Gene name | SH2 domain containing 5 | |
| Gene Alias | SH2D5 | |
| Cytomap | 1p36.12 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6ZV89 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 400745 | SH2D5 | C04 | Human | Oral cavity | OSCC | 6.33e-06 | 3.26e-01 | 0.2633 |
| 400745 | SH2D5 | C21 | Human | Oral cavity | OSCC | 5.81e-05 | 1.76e-01 | 0.2678 |
| 400745 | SH2D5 | C30 | Human | Oral cavity | OSCC | 1.34e-24 | 7.84e-01 | 0.3055 |
| 400745 | SH2D5 | C06 | Human | Oral cavity | OSCC | 1.27e-02 | 3.48e-01 | 0.2699 |
| 400745 | SH2D5 | SYSMH3 | Human | Oral cavity | OSCC | 1.19e-23 | 5.09e-01 | 0.2442 |
| 400745 | SH2D5 | SYSMH5 | Human | Oral cavity | OSCC | 9.25e-09 | 2.46e-01 | 0.0647 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SH2D5 | SNV | Missense_Mutation | c.1228N>T | p.Leu410Phe | p.L410F | Q6ZV89 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.804) | TCGA-A8-A08R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SH2D5 | SNV | Missense_Mutation | c.862G>A | p.Glu288Lys | p.E288K | Q6ZV89 | protein_coding | deleterious(0) | benign(0.001) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SH2D5 | SNV | Missense_Mutation | rs751553158 | c.845N>T | p.Ser282Leu | p.S282L | Q6ZV89 | protein_coding | tolerated(0.69) | benign(0) | TCGA-Z7-A8R6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
| SH2D5 | SNV | Missense_Mutation | novel | c.1255C>A | p.Leu419Met | p.L419M | Q6ZV89 | protein_coding | deleterious_low_confidence(0.04) | possibly_damaging(0.648) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SH2D5 | SNV | Missense_Mutation | c.1219N>G | p.Leu407Val | p.L407V | Q6ZV89 | protein_coding | tolerated_low_confidence(0.06) | benign(0.052) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SH2D5 | SNV | Missense_Mutation | rs751663789 | c.1222N>T | p.Arg408Trp | p.R408W | Q6ZV89 | protein_coding | tolerated_low_confidence(0.16) | benign(0) | TCGA-A6-A567-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
| SH2D5 | SNV | Missense_Mutation | rs760903091 | c.1003N>T | p.Arg335Cys | p.R335C | Q6ZV89 | protein_coding | deleterious(0) | possibly_damaging(0.742) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SH2D5 | SNV | Missense_Mutation | rs750727956 | c.1054N>T | p.Arg352Cys | p.R352C | Q6ZV89 | protein_coding | deleterious(0) | possibly_damaging(0.653) | TCGA-DM-A1D0-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SH2D5 | SNV | Missense_Mutation | rs369171247 | c.661C>T | p.Arg221Cys | p.R221C | Q6ZV89 | protein_coding | tolerated(0.18) | probably_damaging(0.984) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| SH2D5 | SNV | Missense_Mutation | rs745377516 | c.752N>A | p.Arg251His | p.R251H | Q6ZV89 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 400745 | SH2D5 | NA | gemcitabine | GEMCITABINE | 22838950 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |